Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T17:47:23.350Z.
Calculation as of: 2026-10-06T17:47:23.350Z.
Quote observation: 2026-10-06T17:45:15.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2ce25f957fe83095360266a8eba44a0c9f304ca71e6017df3a9cc6b1c586d311
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$408.75M
PS Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$377.39M
PS Ratio
N/A
TTM Avg
4297.49
3Y Avg
4297.49
5Y Avg
4297.49
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MapLight Therapeutics, Inc. (MPLT) | $394.23M | N/A | N/A | N/A | N/A |
| REGENXBIO Inc. (RGNX)vs › | $390.83M | 2.24 | 3.86 | 5.22 | 5.56 |
| Orthofix Medical Inc. (OFIX)vs › | $384.81M | 0.46 | 0.60 | 0.69 | 0.86 |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $408.75M | N/A | N/A | N/A | N/A |
| Carlsmed, Inc. (CARL)vs › | $404.65M | 6.39 | 4.96 | 4.96 | 4.96 |
| Neurogene Inc. (NGNE)vs › | $406.41M | N/A | 482.17 | 482.17 | 482.17 |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $405.74M | N/A | 2.08 | 10.37 | 10.37 |
| Kyverna Therapeutics, Inc. (KYTX)vs › | $377.39M | N/A | 4297.49 | 4297.49 | 4297.49 |
| Rezolute, Inc. (RZLT)vs › | $408.28M | N/A | 0.69 | 0.69 | 0.69 |
| Prothena Corporation plc (PRTA)vs › | $410.17M | 7.52 | 32.56 | 19.45 | 53.61 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-09-30 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-12-31 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-14 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-13 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
